logo
ResearchBunny Logo
Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine

Medicine and Health

Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine

N. Islam, N. E. Sheils, et al.

This study, conducted by Nazmul Islam, Natalie E. Sheils, Megan S. Jarvis, and Kenneth Cohen, reveals that the mRNA-1273 (Moderna) vaccine offers slightly more protection against SARS-CoV-2 infection compared to the BNT162b2 (Pfizer-BioNTech) vaccine, particularly at 90 days post-vaccination, although both vaccines show similar protection against severe outcomes. Dive into the findings of over 3.5 million fully vaccinated individuals!

00:00
00:00
Playback language: English
Abstract
This retrospective cohort study compared the effectiveness of mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 infection in over 3.5 million fully vaccinated individuals. The study found that mRNA-1273 offered slightly more protection against infection than BNT162b2, reaching statistical significance at 90 days post-vaccination. However, no difference was observed in protection against hospitalization, ICU admission, or death between the two vaccines.
Publisher
Nature Communications
Published On
Nov 16, 2022
Authors
Nazmul Islam, Natalie E. Sheils, Megan S. Jarvis, Kenneth Cohen
Tags
mRNA-1273
BNT162b2
SARS-CoV-2
vaccination
effectiveness
COVID-19
comparison
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny